Darwin Global Management, Ltd.
CIK 1839209 · View on SEC EDGAR ↗
- Portfolio value
- $3.8B
- Positions
- 5
- As of
- June 30, 2026
Portfolio value QoQ: -0.3% 13F does not disclose cash
- Top 10 holdings weight
- 100.00%
- Top 25 holdings weight
- 100.00%
- Positions above 1%
- 5
- Effective number of positions
- 2.8
Based on 13F long-equity holdings only (cash, bonds, shorts not disclosed)
Turnover Q2 2026: 28.94% Est. buys $1,639,272,763 · sells $1,089,768,059
Median holding: 1.0 quarters Tracked Q4 2024–Q2 2026 · 27.8% still held
- New positions
- 0
- Increased
- 3
- Decreased
- 2
- Closed
- 1
On this page
- Performance vs S&P How this manager's 13F portfolio performed against the S&P 500.
- Sector breakdown How the portfolio splits across market sectors.
- Portfolio Every stock this institution reports holding, from its latest 13F.
- High-conviction bets The holdings this manager is most concentrated in.
- Top moves The biggest position increases and decreases this quarter.
- Exited positions Positions the manager fully sold out of last quarter.
- Related The person behind this filer, where we can match one.
Performance vs S&P 500
Annualized: +63.9% · S&P 500: +18.0%
Approximates a buy-and-hold portfolio built from quarterly SEC 13F snapshots. Excludes cash, short positions, options/derivatives, and non-13(f) securities — reflects the disclosed long-equity book only, not total fund AUM. SEC filing lag is up to 45 days; this is not a real-time-copyable timing.
Priceable coverage: 98.7% · Options excluded: 0.0%
Sector breakdown
Full portfolio 5 positions
| Type | Streak | 8Q trend | |||||
|---|---|---|---|---|---|---|---|
| RVMD Revolution Medicines, Inc. - Common Stock | $2,047,516,314 | 54.45% | 10,629,822 | $1,842,532,835 | Up ×1 | ||
| INSM Insmed Incorporated - Common Stock | $673,600,013 | 17.91% | 6,431,163 | $-1,902,970,798 | Down ×2 | ||
| BLTE Belite Bio, Inc - American Depositary Shares | $456,588,244 | 12.14% | 3,077,219 | $483,522 | Up ×2 | ||
| ABVX Abivax SA - American Depositary Shares | $348,215,205 | 9.26% | 3,621,583 | $-3,853,481 | Up ×3 | ||
| ROIV Roivant Sciences Ltd. - Common Shares | $234,333,729 | 6.23% | 6,747,300 | $54,817,036 | Down ×1 | ||
| No matches | |||||||
Conviction holdings
Positions increased for 3+ consecutive quarters.
Share counts are as reported in 13F filings (not split-adjusted)
| Security | Value | % of portfolio | Streak |
|---|---|---|---|
| ABVX | $348,215,205 | 9.26% | up ×3 |
Top movers (QoQ)
| Security | Action | Shares Δ | Value Δ |
|---|---|---|---|
| INSM | Trimmed | -10.4M | -$1.9B |
| ROIV | Trimmed | -50K | +$54.8M |
| ABVX | Bought more | +153K | -$3.9M |
| BLTE | Bought more | +20K | +$484K |
1 position hidden (data completeness check)
Exited positions
Includes corporate events (mergers, delistings) — not all exits are sells
Closed positions reflect 13F reporting changes; for index managers these are often mechanical (delisting, M&A, index rebalancing), not active decisions.
| Security | Quarter | Shares before | Value before | Price since exit |
|---|---|---|---|---|
| VRNA | Sept. 30, 2025 | 4,129,618 | $387,440,761 | No longer tracked |
| UTHR | Dec. 31, 2025 | 748,550 | $317,617,251 | 9.5% |
| CDTX | March 31, 2026 | 997,196 | $220,180,877 | No longer tracked |
| WVE | March 31, 2026 | 7,298,421 | $125,167,920 | -25.1% |
| JAZZ | March 31, 2025 | 484,515 | $59,668,022 | 105.3% |
| GERN | March 31, 2025 | 9,569,835 | $33,877,216 | -0.9% |
| KROS | March 31, 2025 | 1,687,135 | $26,707,347 | 6.6% |
| QURE | Dec. 31, 2025 | 400,000 | $23,760,000 | 97.2% |
| CAPR | March 31, 2026 | 800,000 | $23,168,000 | -74.7% |
| MRUS | Sept. 30, 2025 | 395,738 | $20,970,157 | No longer tracked |
| ALLO | Sept. 30, 2025 | 10,479,791 | $12,366,153 | 71.4% |
| NRIX | March 31, 2025 | 163,681 | $3,083,750 | 131.4% |
| DNTH | June 30, 2026 | 17,357 | $1,456,599 | 19.0% |